Minerva Neurosciences GAAP EPS of -$25.51
Source: SeekingAlpha
2026-03-11 07:12:20 ET
More on Minerva Neurosciences
- Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia - Slideshow
- Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript
- Seeking Alpha’s Quant Rating on Minerva Neurosciences
- Historical earnings data for Minerva Neurosciences
- Financial information for Minerva Neurosciences
Read the full article on Seeking Alpha
For further details see:
Minerva Neurosciences GAAP EPS of -$25.51
Minerva Neurosciences Inc
NASDAQ: NERV
NERV Trading
1.64% G/L:
$7.745 Last:
99,515 Volume:
$7.27 Open:
NERV Latest News
March 12, 2026 07:00:00 am
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
March 11, 2026 07:00:00 am
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
March 04, 2026 07:00:00 am
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
NERV Stock Data
$270,897,731
30,421,902
0.02%
9
N/A
Biotechnology & Life Sciences
Healthcare
US
Burlington
